S ustained hypertension causes vascular injury and atherosclerosis that are mediated by multiple mechanisms. Although numerous factors participate in these disease processes, angiotensin II (Ang II) has emerged as an important growth factor that regulates cell proliferation. 1 Ang II is responsible for the inflammatory response and cell migration by producing various cytokines and adhesion molecules 2 and by direct effects on monocyte/macrophages. 3 Of interest, recent studies have witnessed that Ang II also activates Rho-kinase, 4, 5 an effector of the small G protein Rho, which not only plays an important role in calcium sensitization of vascular smooth muscle cells (VSMCs) but also shares the facilitatory action on cell adhesion, 6 proliferation, and migration 7 with Ang II. Because excessive cellular proliferation and migration within the arterial wall are established as a central mechanism for the development of atherosclerosis, 8, 9 Ang II would contribute, whether directly or indirectly, to the development of vascular injury as a local detrimental factor, as well as a systemic hemodynamic hormone.
A growing body of evidence has accrued that p27, which plays a crucial role in cell proliferation as an inhibitor of cyclin/cyclin-dependent kinase complexes, 10 participates in the regulation of vascular injury. The p27 expression inversely correlates with proliferation of macrophages and VSMCs within human atherosclerotic tissue. 11 Mice doubly deficient for p27 and apolipoprotein E display accelerated atherogenesis with augmented proliferation of macrophages and VSMCs. 12 In addition, p27 is reported to be a negative regulator of migration. 13 The p27 expression is downregulated in infiltrating leukocytes after balloon injury. 14 Targeted disruption of bone marrow p27 enhanced arterial leukocytes infiltration and inflammatory response, resulting in accelerated vascular injury. 14, 15 Of note, p27 expression is downregulated by Rho-kinase activation, leading to acceleration of the cell cycle progression. 16 -18 Rho/Rho-kinase pathway is reported to mediate cell migration, partly through p27-dependent pathways. 13 Nevertheless, the effect of Ang II on p27 expression remains a matter of controversy, 19 -21 and definite evidence linking Rho/Rho-kinase pathway and p27 in mediating the Ang II-induced cellular proliferation and migration has not been accumulated.
The current study was designed to elucidate directly the role of p27 in Ang II-induced vascular injury. To clarify this issue, we used homozygous p27-deficient (p27KO) mice. We also examined whether Rho-kinase mediated the Ang IIinduced changes in p27 expression and vascular injury with a selective Rho-kinase inhibitor, fasudil.
Methods

Animal Study
This study was performed in accordance with the animal experimentation guideline of Keio University School of Medicine. The role of p27 in Ang II-induced vascular injury and the interaction between p27 and Rho-kinase were evaluated in p27KO mice. Mice heterozygous for the p27 gene with C57BL/6 genetic background were kindly supplied by Nippon Roche Research Center (Kanakura, Japan). 22 Male mice homozygous for the p27 gene and wild-type (WT) mice were selected from the offspring of heterozygous mating. The genotype was determined by polymerase chain reaction analysis on DNA isolated from tail biopsy specimens. 22 Alzet osmotic minipumps (model 1002; Durect Corporation, Cupertino, Calif) were implanted into WT and p27KO mice at 2 months of age under anesthesia with inhaled isoflurane. 23 Pumps were filled either with saline vehicle or with solutions of Ang II (Sigma-Aldrich, St. Louis, Mo) that delivered subcutaneously 1500 ng/kg per minute of Ang II for 14 days. Fasudil (30 mg/kg per day; Asahi Kasei, Tokyo, Japan) was given in drinking water for 14 days. Fasudil was used for Rho-kinase inhibition because it is the only Rho-kinase inhibitor practically available for long-term in vivo use. This agent acquires unique characteristics when administered in vivo; its metabolite, hydroxy fasudil, still retains its activity and possesses a more selective action than its parent drug on Rho-kinase. Thus, its specificity for Rho-kinase is 100-times higher for PKC and 1000-times higher for myosin light chain kinase. 4, 24, 25 It is unequivocal that selective inhibition for Rho-kinase is reasonably practiced by the treatment with fasudil.
The systolic blood pressure was measured by the tail-cuff method using an automatic sphygmomanometer (Softron BP-98A; Softron, Tokyo, Japan). Before each measurement, mice were placed in a Plexiglas cage and subsequently heated at 37°C for 5 minutes.
Microscopic Analysis
For morphometric analysis of vascular hyperplasia, sections were stained with hematoxylin and eosin. Three serial sections from the abdominal aorta of each animal were photographed and stored in a digital format. Arterial wall thickness was measured in a blinded fashion with Scion Image software (Scion Corp., Frederick, Md). 26 
Immunohistochemistry
Immunohistochemical analysis of aortic cross-sections were performed using antibodies against Mac-3 (1:50, sc-19991; Santa Cruz Biotechnology, Santa Cruz, Calif), proliferating cell nuclear antigen (PCNA) (1:50, sc-7907; Santa Cruz Biotechnology), and p27 (1:800; sc-528; Santa Cruz Biotechnology). 18 Quantification of nuclear staining for Mac3, PCNA, and p27 was performed from 4 to 6 independent aortic sections in each group. Mac 3-positive, PCNApositive, and p27-positive cells were counted by computer-aided planimetry using the Scion Image software. 18 
Statistical Analysis
Data are expressed as meanϮSEM. Data were analyzed by 1-way or 2-way ANOVA as appropriate, followed by Bonferroni multiple comparison post hoc test. PϽ0.05 was considered statistically significant.
Results
Ang II-Induced Changes in Blood Pressure and the Effects of Fasudil Treatment
Baseline systolic blood pressure was comparable between p27KO mice (113Ϯ2 mm Hg, nϭ6) and WT mice (110Ϯ2 mm Hg, nϭ6). Two-week Ang II infusion elicited similar magnitude of elevations in systolic blood pressure in WT mice (159Ϯ5 mm Hg; PϽ0.01) and p27KO mice (157Ϯ5 mm Hg; PϽ0.01). The treatment with fasudil (30 mg/kg per day) had no effect on the changes in blood pressure in either WT (156Ϯ3 mm Hg) or p27KO mice (154Ϯ3 mm Hg).
p27 Expression in the Vascular Tissues of Ang IIInfused Mice
Two-week Ang II infusion reduced the p27 expression in the aortic tissue from WT mice compared with that in WT mice with vehicle infusion ( Figures 1A and 1B ). Simultaneous treatment with fasudil upregulated the p27 expression ( Figure  1C ). When these results are summarized, Ang II-induced downregulation of p27 was partially restored by a subdepressor dose of fasudil ( Figure 1E ).
Ang II-Induced Medial Thickness
To elucidate the role of p27 in Ang II-induced hypertension, we also infused Ang II to the p27KO mice. With the vehicle infusion, the medial thickness of the aorta in the p27KO mice 
Ang II-Induced Vascular Proliferation
We 
Ang II-Induced Accumulation of Macrophages
We next examined the accumulation of macrophages within the vascular tissues as assessed by Mac-3 staining. In mice treated with vehicle alone, no difference in the number of positive-staining cells was noted between WT and p27KO 
Discussion
In the present study, we have demonstrated that p27KO mice manifest higher susceptibility to the vascular remodeling action of Ang II. This effect is accompanied by the enhanced accumulation of PCNA-positive cells and macrophage infiltration. Furthermore, in WT mice, chronic inhibition of Rho-kinase by fasudil upregulates the p27 expression level and ameliorates the Ang II-induced cell proliferation and macrophage infiltration within the vascular wall, independent of systemic blood pressure, but these effects are diminished in p27-deficient mice. These results indicate that p27 constitutes an important modulator of the progression of vascular remodeling and is under the regulation of Rho-kinase activity that mediates a part of the vascular action of Ang II. 4, 5 The strategy to increase the expression of p27 by the treatment with Rho-kinase inhibitor is expected to offer a promising approach to the treatment of cardiovascular diseases.
Although originally discovered as a potent vasoconstrictor substance, Ang II induces cell growth and migration that would precipitate vascular injury. One of the mechanisms for the growth-promoting and promigratory effects of Ang II is downregulation of p27. 1 The results presented here show that Ang II induces the proliferation of vascular cells and decreases p27 expression in WT mice (Figures 1 and 3) , a finding in good agreement with previous in vitro and in vivo reports by other laboratories. 19, 21 In the present study, medial thickness, cell proliferation, and macrophage infiltration are similar in saline-infused WT and p27 KO mice, which coincides with the demonstration by Diez-Juan et al. 12 In contrast, Ang II-induced cell proliferation and macrophages infiltration in the vascular wall is augmented in p27KO mice (Figures 3 and 4) . Because the p27-positive cells (Figure 1 ) are supposed to be VSMCs or infiltrated macrophages, 11 it is likely that decreased p27 expression in the vascular tissues plays an important role only in the pathological state. 12, 14 Enhanced cell proliferation in p27KO mice indicates the contribution of additional factors to the Ang II-induced vascular proliferation; Ang II downregulates another cyclindependent kinase inhibitor, p21, 21 and upregulates cyclin D1, a cell cycle-positive regulator, 19 which might enhance proliferation in Ang II-infused p27KO mice. In concert, the inverse relationship between the p27 expression level and cell proliferation/macrophage migration lends support to the formulation that p27 contributes, at least in part, to the regulation of cell proliferation and migration as an inhibitory factor in Ang II-induced vascular remodeling and inflammation. Of interest, we found that macrophage infiltration was augmented in p27KO mice, particularly in adventitial regions (Figure 4 ), which could contribute to the increased medial thickness. 26 A therapeutic strategy for targeting p27 expression has not been fully elucidated. It has been demonstrated that multiple factors affect p27 expression and the subsequent progression of vascular injury. 13, 16, 27 Among these, Rho-kinase pathway has attracted much attention because it promotes cell cycle progression, possibly through destabilizing p27. 17 Moreover, Rho/Rho-kinase pathway mediates migration through p27-dependent and independent pathways. 13 Thus, several studies, including that of our laboratory, have reported that direct inhibition of Rho-kinase pathway increases the p27 expression and inhibits the proliferation of various cells and the infiltration of macrophages. 16 -18 In the present study, we have found that fasudil, a Rho-kinase inhibitor, restores the decreased p27 level induced by chronic Ang II infusion ( Figure  1 ) and reduces PCNA (Figure 3 ) and Mac-3-positive cells in the vascular wall (Figure 4 ). In addition, these vascular protective effects of fasudil were attenuated in p27KO mice compared with WT mice. Although fasudil at the dose used in the present study (ie, 30 mg/kg per day) did not alter systemic blood pressure, this agent possesses hypotensive action and is demonstrated to reduced blood pressure. 28 The inhibition of Rho-kinase therefore would prevent vascular injury in Ang II-induced hypertension through p27-dependent pathway, as well as hypotensive action.
Of importance, both antiproliferative and antimigratory effects by fasudil were observed in p27KO mice. These observations indicate that the inhibition of Rho-kinase can decrease vascular proliferation and macrophage infiltration through p27-independent mechanism. In this regard, some of the Ang II-related proliferative effects are mediated by redox-sensitive pathway, 21 and Rho-kinase pathway is involved in the upregulation of NAD(P)H oxidase expression. 4 Additionally, inhibition of Rho-kinase prevents the expression of MCP-1, 5 which is implicated as promigratory factor in Ang II-induced monocyte/macrophages recruitments. 26, 29 These mechanisms could be responsible for the antiproliferative or antimigratory effect of fasudil in Ang II-infused p27KO mice. Alternatively, Ang II-induced downregulation of p27 may not completely depend on the activation of Rho/Rho-kinase signal transduction. 30 Although precise mechanisms remain undetermined, it is reasonable to conclude that the inhibition of Rho-kinase by fasudil suppresses the proliferation of vascular cells and the macrophage infiltration through multiple mechanisms, including p27-dependent pathway.
Finally, the mechanism whereby Ang II accelerates atherosclerosis merits comment. As detailed, Ang II has direct effects on cellular components of the arterial wall. 1,2 However, Ang II would facilitate vascular injury through the mechanical stress that occurs as a result of elevated systemic blood pressure. 31 Although Ang II elevates systemic blood pressure to the same level in p27KO and WT mice, the possibility remains that p27KO mice are more susceptible to vascular injury through mechanical stress. 32 It is also possible that Ang II stimulates VSMCs proliferation indirectly through the synthesis of autocrine growth factors, including platelet-derived growth factor, 33 because platelet-derived growth factor causes VSMC proliferation through Rho/Rhokinase-induced downregulation of p27. 17 Further investigations are required to clarify these issues.
Perspectives
Targeting vascular cell proliferation and migration constitutes a potential therapeutic approach to the prevention of vascular remodeling and inflammation. Our present study supports the notion that decreased p27 levels act as a pro-inflammatory and pro-atherosclerotic factor in Ang II-induced hypertension. Our findings also indicate that the chronic inhibition of Rho-kinase offers cardiovascular protection, partially through the restoration of p27 expression and partially through the p27-independent mechanism. It will be of potential importance in future works to address whether targeting p27 and/or Rho/Rho-kinase pathway in cardiovascular disease will yield therapeutic benefits in clinical trials.
